Sozinibercept
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats[1][2][3].
Product Specifications
CAS Number
2568358-31-4
Product Name Alternative
OPT 302; VGX-300
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sozinibercept.html
Purity
98.52
Solubility
10 mM in DMSO
Smiles
[Sozinibercept]
Molecular Weight
(120.85 kDa)
References & Citations
[1]Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56 (7) : 4802-4802. |[2]Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55 (13) : 1823-1823. |[3]Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60 (9) : 3667-3667.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040009-100 1x 100 µL
MART-1 / Melan-A (M2-7C10), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC742946-500 1x 500 µL
TLE1 (Synovial Sarcoma Marker) (TLE1/2946R), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details